RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justified
Tweet Send to a Friend
RBC Capital analyst Trung Huynh reiterated an Outperform rating and $1,250.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
